Nateglinide (CAS 105816-04-4) Suppliers and Product Information

Nateglinide is a rapid-acting oral antidiabetic agent used for the treatment of type 2 diabetes mellitus. It belongs to the meglitinide class of drugs and works by stimulating insulin release from pancreatic beta cells. Nateglinide has a rapid onset and short duration of action, making it effective for controlling postprandial glucose levels.

Frequently Asked Questions about Nateglinide

What is the mechanism of action of Nateglinide?

Nateglinide works by binding to the sulfonylurea receptor on pancreatic β-cells, blocking ATP-sensitive potassium channels. This leads to membrane depolarization, causing calcium channels to open and promoting insulin secretion.

What are the main uses of Nateglinide?

Nateglinide is primarily used for the treatment of type 2 diabetes mellitus, especially in patients where diet, exercise, and other oral antidiabetic agents have not provided adequate glycemic control.

What are the pharmacokinetic properties of Nateglinide?

Nateglinide has an oral bioavailability of 72%, with effects appearing within 15-20 minutes of administration. Its plasma protein binding rate is 99%, and it has a short half-life of 1.5 to 1.7 hours. It is primarily metabolized in the liver and excreted through feces and urine.

Are there any significant drug interactions with Nateglinide?

Yes, nateglinide may interact with certain antibiotics (e.g., rifampicin), antifungals (e.g., fluconazole), and lipid-lowering agents (e.g., gemfibrozil). These interactions can affect the hypoglycemic effect of nateglinide.

What are the advantages of Nateglinide compared to other antidiabetic drugs?

Nateglinide has a rapid onset and short duration of action, which allows for more flexible meal planning. It has a lower risk of hypoglycemia and fewer cardiovascular side effects compared to some other antidiabetic medications.